Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 290Glioblastoma 260Glioma 202Neuroblastoma 88Neoplasms 62Astrocytoma 56Central Nervous System Neoplasms 54Medulloblastoma 48Breast Neoplasms 44Melanoma 40Sarcoma 39Meningioma 39Neurofibromatosis 1 38Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 37Ependymoma 36Osteosarcoma 31Rhabdomyosarcoma 30Neoplasm Metastasis 28Sarcoma, Ewing 27Rhabdoid Tumor 27Diffuse Intrinsic Pontine Glioma 27Recurrence 26Oligodendroglioma 23Gliosarcoma 22Wilms Tumor 21Pancreatic Neoplasms 21Pheochromocytoma 20Hepatoblastoma 20Neurofibroma, Plexiform 19

Interventions

ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1palbociclib 1olaparib 1larotrectinib 1ivosidenib 1erdafitinib 1ensartinib 1X-Rays 1Vemurafenib 1Specimen Handling 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1LY3023414 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xanthogranuloma, Juvenile × CNS × 90 days × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡